LifeVantage Corporation (LFVN) is asking stockholders to vote at its fiscal 2027 Annual Meeting, to be held in person on November 5, 2026 at 1:00 p.m. MT in Lehi, Utah, on three main items: electing six directors, approving a non‑binding Say‑On‑Pay vote on executive compensation, and ratifying Deloitte & Touche LLP as independent auditor for the year ending June 30, 2027.
The record date is September 14, 2026, when 12,589,444 common shares were outstanding. The board, led by independent chair Raymond Greer, highlights recent governance and strategy changes, including leadership transition to new CEO Terrence Moorehead, board refreshment, majority voting for directors, high director stock‑ownership guidelines, and expanded stockholder engagement. 2026 pay for former CEO Steven Fife totaled $2.19 million, while Chief Sales Officer Kristen Cunningham and CFO Carl Aure earned $815,439 and $756,663, respectively, with a mix of base salary, annual incentives at 10% of target, and performance‑based equity.
Lifevantage Corp (LFVN) reports that director Lewis Darwin purchased common stock in the company. On September 15, 2026, he bought 976 shares at $6.22 per share in an open-market or private transaction, increasing his directly held stake to 138,244 shares. The filing affirms that this trade was made under a Rule 10b5-1 trading plan.
Lifevantage Corp (LFVN) reported that its Chief Financial Officer, Carl Aure, had 1,869 shares of common stock withheld or delivered on September 10, 2026 to pay the exercise price or related tax liability at a reported price of $6.37 per share. After this transaction, he held 156,495 shares directly, which include 2,810 shares purchased on August 31, 2026 under the Employee Stock Purchase Plan. No Rule 10b5-1 trading plan is reported for this transaction.
Lifevantage Corp (LFVN) reported that Chief Sales Officer Kristen Cunningham executed several transactions in the company’s common stock. On September 14, 2026, she sold 8,901 shares at a weighted average price of $6.18 per share, with individual trade prices ranging from $6.15 to $6.26. She also sold 100 shares at $6.41 on September 11, 2026, and on September 10, 2026, 2,254 shares were delivered or withheld for payment of exercise price or tax liability at $6.37 per share. No Rule 10b5-1 trading plan is reported for these transactions.
LifeVantage Corp (LFVN) reported materially weaker results for the fourth quarter and full fiscal year ended June 30, 2026. Q4 revenue was $42.4 million, down 23.1% year over year, with Americas revenue down 24.8% and Asia/Pacific & Europe down 16.9%. Q4 net income was $1.3 million or $0.10 per diluted share, versus $0.15 a year ago, and adjusted EBITDA fell to $2.7 million from $4.8 million.
For fiscal 2026, revenue was $182.6 million, a 20.1% decline from 2025, driven by lower MindBody GLP-1 System sales, fewer orders, and smaller average order size, partially offset by the LoveBiome acquisition. Net income dropped to $5.1 million ($0.40 per diluted share) from $9.8 million ($0.75), and adjusted EBITDA decreased to $13.7 million from $22.1 million. Gross margin remained high at 77.6%, and the company ended the year with $14.9 million in cash, no debt, and $10.2 million of operating cash flow. Active accounts declined 21.2% to 104,000. LifeVantage repurchased about 336,000 shares for $2.0 million and is not issuing fiscal 2027 guidance following a CEO transition.
LifeVantage Corporation (LFVN) reports on its fiscal year ended June 30, 2026, highlighting a direct-selling nutrigenomics business focused on dietary supplements, skin and hair care, energy drinks, gut health, and pet products. The company operates primarily through independent consultants across the Americas, Asia/Pacific, and Europe.
Net revenue was $182.6 million, down from $228.5 million in 2025, with the Americas contributing 78.2% and Asia/Pacific & Europe 21.8%. U.S. sales represented about 74% of revenue and Japan about 13%. LFVN closed Hong Kong and Singapore on May 31, 2026 and expanded into Iceland and Portugal.
The company launched multiple new products and systems, including the patent-pending P84 System for gut health and the MindBody GLP-1 System for weight management, and integrated assets acquired from LoveBiome. It continued rolling out its “Evolve” compensation plan and expanded its Rewards Circle loyalty program. As of August 26, 2026, 12,527,348 common shares were outstanding; non-affiliate market value was approximately $63.7 million as of December 31, 2025. The filing outlines extensive regulatory, operational, technology, and direct-selling risks.
Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation report beneficial ownership of 669,418 shares of Lifevantage Corp common stock, representing 5.31% of the outstanding class. The securities relate to Lifevantage Corp’s common stock with a par value of $0.0001 per share.
Renaissance Technologies LLC holds sole voting power and sole dispositive power over all 669,418 shares, with no shared voting or dispositive power. Certain funds managed by Renaissance Technologies LLC have the right to receive dividends and proceeds from any sale of these Lifevantage shares.
Moorehead Terrence reported acquisition or exercise transactions in this Form 4 filing.
Lifevantage Corp granted President and CEO Terrence Moorehead equity awards on August 6, 2026. He received 308,642 shares of common stock as a stock unit award that vests in three equal installments on August 6 of 2027, 2028, and 2029, subject to continued service. He was also granted 540,123 Performance Restricted Stock Units (PRSUs), each representing one share of common stock. These PRSUs vest only if specified financial performance targets are achieved over a three-year period from August 6, 2026 to August 6, 2029, with 10% vesting at each achievement date and an additional 10% vesting on the first anniversary of each such achievement date, contingent on continued service.
Lifevantage Corp filed an initial statement of beneficial ownership for Terrence Moorehead, who is identified as a director and as the company’s President and CEO. The filing reports no specific shareholdings or transactions at this time and includes an exhibit titled Power of Attorney.